新医改下我国促进罕见病药品可及性的激励政策体系及其影响分析*

赵宇航,黄锐,王青婷,徐家童,张雯雯,龚时薇

Incentive Policy System and Its Impact Analysis on Promoting the Accessibility of Orphan Drugs in China

Yuhang ZHAO,Rui HUANG,Qingting WANG,Jiatong XU,Wenwen ZHANG,Shiwei GONG

图1 2016—2021年我国上市罕用药的审批类型与数量

Fig.1 Type and number of reviews and approvals of orphan drugs marketed in China from 2016 to 2021